JEXELVI Trademark

Trademark Overview


On Thursday, September 3, 2020, a trademark application was filed for JEXELVI with the United States Patent and Trademark Office. The USPTO has given the JEXELVI trademark a serial number of 90156847. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 15, 2021. This trademark is owned by Pfizer Inc.. The JEXELVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of alopecia areata, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis
jexelvi

General Information


Serial Number90156847
Word MarkJEXELVI
Filing DateThursday, September 3, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 15, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 16, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of alopecia areata, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 8, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events


Event DateEvent Description
Monday, November 15, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 15, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 13, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 16, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 27, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 8, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 7, 2021ASSIGNED TO EXAMINER
Thursday, October 8, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 7, 2020NEW APPLICATION ENTERED IN TRAM